Adenovirus serotype 5-vectored foot-and-mouth disease subunit vaccines: The first decade

Future Virology

Volumn 5, Issue 1, 2010, Pages 51-64

  Grubman, Marvin J ^a   Moraes, Mauro P ^a   Schutta, Christopher ^a   Barrera, Jose ^b   Neilan, John ^a   Ettyreddy, Damodar ^c   Butman, Bryan T ^c   Brough, Douglas E ^c   Brake, David A ^d  

^a PLUM ISLAND ANIMAL DISEASE CENTER   (United States)

^b The McConnell Group Inc   (United States)

^c GENVEC INC   (United States)

^d BioQuest Associates LLC   (United States)

Author keywords

Foot and mouth disease virus; Replication defective adenovirus; Subunit vaccines

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; FOOT AND MOUTH DISEASE VACCINE; NONSTRUCTURAL PROTEIN 2; PLACEBO; PROTEINASE;

CATTLE; DRUG APPROVAL; DRUG EFFICACY; DRUG MANUFACTURE; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; FOOT AND MOUTH DISEASE; FOOT AND MOUTH DISEASE VIRUS; HUMAN ADENOVIRUS 5; INFECTION PREVENTION; INOCULATION; LICENSING; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; REVIEW; SEROCONVERSION; SEROTYPE; SWINE; UNITED STATES; VIRUS CAPSID; VIRUS REPLICATION; VIRUS SHEDDING; VIRUS TRANSMISSION;

ADENOVIRIDAE; ANIMALIA; BOS; FOOT-AND-MOUTH DISEASE VIRUS; HUMAN ADENOVIRUS; MIRIDAE; SUIDAE;

EID: 74049151158     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/fvl.09.68     Document Type: Review

References (29)

1. Grubman MJ, Baxt B: Foot-and-mouth disease. Clin. Microbiol. Rev. 17, 465-493 (2004). ■■ Describes the disease, its pathogenesis and molecular biology of foot-and-mouth disease virus (FMDV).
2. Kitching RP: A recent history of foot-and-mouth disease. J. Comp. Pathol. 118, 89-108 (1998).
3. Mayr GA, Chinsangaram J, Grubman MJ: Development of replication-defective adenovirus serotype 5 containing the capsid and 3C protease coding regions of foot-and-mouth disease virus as a vaccine candidate. Virology 263, 496-506 (1999).
4. Grubman MJ, Morgan DO, Kendall J, Baxt B: Capsid intermediates assembled in a foot-and-mouth disease virus genome RNA-programmed cell-free translation system and in infected cells. J. Virol. 56, 120-126 (1985).
5. Rowlands DJ, Sangar DV, Brown F: A comparative chemical and serological study of the full and empty particles of foot-and-mouth disease virus. J. Gen. Virol. 26, 227-238 (1974).
6. Rweyemamu MM, Terry G, Pay TW: Stability and immunogenicity of empty particles of foot-and-mouth disease virus. Arch. Virol. 59, 69-79 (1979).
7. Grubman MJ: Development of novel strategies to control foot-and-mouth disease: marker vaccines and antivirals. Biologicals 33, 227-234 (2005).
8. Prevec L, Schneider M, Rosenthal KL, Belbeck LW, Derbyshire JB, Graham FL: Use of human adenovirus-based vectors for antigen expression in animals. J. Gen. Virol. 70(Pt 2), 429-434 (1989).
9. Graham FL, Smiley J, Russell WC, Nairn R: Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36, 59-74 (1977).
10. Brough DE, Lizonova A, Hsu C, Kulesa VA, Kovesdi I: A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4. J. Virol. 70, 6497-6501 (1996).
11. Mayr GA, O'Donnell VO, Chinsangaram J, Mason PW, Grubman MJ: Immune responses and protection against foot-and-mouth disease virus (FMDV) challenge in swine vaccinated with adenovirus-FMDV constructs. Vaccine 2152-2162 (2001).
12. Moraes MP, Mayr GA, Mason PW, Grubman MJ: Early protection against homologous challenge after a single dose of replication-defective human adenovirus type 5 expressing capsid proteins of foot-and-mouth disease virus (FMDV) strain A24. Vaccine 20, 1631-1639 (2002). ■ Presents the first demonstration that one dose of adenovirus serotype 5 (Ad5)-A24 vector can protect swine when challenged 7 days later.
13. Pacheco JM, Brum MC, Moraes MP, Golde WT, Grubman MJ: Rapid protection of cattle from direct challenge with foot-and-mouth disease virus (FMDV) by a single inoculation with an adenovirus-vectored FMDV subunit vaccine. Virology 337, 205-209 (2005). ■ Presents the first demonstration that one dose of Ad5-A24 vector can protect cattle when challenged 7 days later.
14. Caron L, Brum MCS, Moraes MP, Golde WT, Arns CW, Grubman MJ: Granulocyte-machrophage colony-stimulating factor does not increase the potency or efficacy of a foot-and-mouth disease virus subunit vaccine. Pesqui. Vet. Bras. 23, 150-158 (2005).
15. Pay TW, Hingley PJ: Correlation of 140S antigen dose with the serum neutralizing antibody response and the level of protection induced in cattle by foot-and-mouth disease vaccines. Vaccine 5, 60-64 (1987).
16. Doel TR, Williams L, Barnett PV: Emergency vaccination against foot-and-mouth disease: rate of development of immunity and its implications for the carrier state. Vaccine 12, 592-600 (1994).
17. Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, Tough DF: Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14, 461-470 (2001).
18. Proietti E, Bracci L, Puzelli S et al.: Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model. J. Immunol. 169, 375-383 (2002).
19. Cull VS, Broomfield S, Bartlett EJ, Brekalo NL, James CM: Coimmunisation with type I IFN genes enhances protective immunity against cytomegalovirus and myocarditis in gB DNA-vaccinated mice. Gene Ther. 9, 1369-1378 (2002).
20. de Avila Botton S, Brum MC, Bautista E et al.: Immunopotentiation of a foot-and-mouth disease virus subunit vaccine by interferon a. Vaccine 24, 3446-3456 (2006).
21. Lu Z, Bao H, Cao Y et al.: Protection of guinea pigs and swine by a recombinant adenovirus expressing O serotype of foot-and-mouth disease virus whole capsid and 3C protease. Vaccine 26(Suppl. 6), G48-G53 (2008).
22. Pena L, Moraes MP, Koster M et al.: Delivery of a foot-and-mouth disease virus empty capsid subunit antigen with nonstructural protein 2B improves protection of swine. Vaccine 26, 5689-5699 (2008).
23. Gall JG, Crystal RG, Falck-Pedersen E: Construction and characterization of hexon-chimeric adenoviruses: specification of adenovirus serotype. J. Virol. 72, 10260-10264 ( 98).
24. Gall JG, Lizonova A, EttyReddy D et al.: Rescue and production of vaccine and therapeutic adenovirus vectors expressing inhibitory transgenes. Mol. Biotechnol. 35, 263-273 (2007). ■■ Describes the construction and production of adenovirus-based vaccines and therapeutics, which express transgene products that are inhibitory to the growth of adenovectors.
25. Boldwell C, Brown AL, Barnett PV et al.: Host cell selection of antigenic variants of foot-and-mouth disease virus. J. Gen. Virol. 70, 45-57 (1989).
26. Gogev S, Vanderheijden N, Lemaire M et al.: Induction of protective immunity to bovine herpesvirus type 1 in cattle by intranasal administration of replication-defective human adenovirus type 5 expressing glycoprotein gC or gD. Vaccine 20, 1451-1465 (2002).
27. Moraes MP, Chinsangaram J, Brum MC, Grubman MJ: Immediate protection of swine from foot-and-mouth disease: a combination of adenoviruses expressing interferon α and a foot-and-mouth disease virus subunit vaccine. Vaccine 22, 268-279 (2003).
28. Wu Q, Moraes MP, Grubman MJ: Recombinant adenovirus co-expressing capsid proteins of two serotypes of foot-and-mouth disease virus (FMDV): in vitro characterization and induction of neutralizing antibodies against FMDV in swine. Virus Res. 93, 211-219 (2003).
29. US Department of Agriculture Center for Veterinary Biologics (2008). www.aphis.usda.gov/animal-health/vet- biologics/vb-sifs.shtml